Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Publication for its Hong Kong patent protecting AVERSA™ abuse-deterrent transdermal technology. The patent, assigned Publication Number 40085268 B, will be published on December 20, 2024. AVERSA™ technology is now protected by patents in 46 countries, including major markets. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs like opioids and stimulants. Nutriband is developing AVERSA™ Fentanyl with Kindeva Drug Delivery, potentially becoming the world's first abuse-deterrent opioid patch with projected annual US sales of $80-200 million.
Nutriband Inc. (NASDAQ:NTRB) ha ricevuto un avviso di pubblicazione per il suo brevetto a Hong Kong che protegge la tecnologia transdermica deterrente per l'abuso AVERSA™. Il brevetto, assegnato con il numero di pubblicazione 40085268 B, sarà pubblicato il 20 dicembre 2024. La tecnologia AVERSA™ è ora protetta da brevetti in 46 paesi, compresi i mercati principali. Questa tecnologia incorpora agenti aversivi nei cerotti transdermici per prevenire l'abuso di farmaci come oppiacei e stimolanti. Nutriband sta sviluppando AVERSA™ Fentanyl in collaborazione con Kindeva Drug Delivery, potenzialmente diventando il primo cerotto antidroga deterrente al mondo con vendite annue previste negli Stati Uniti tra 80 e 200 milioni di dollari.
Nutriband Inc. (NASDAQ:NTRB) ha recibido un Aviso de Publicación de su patente en Hong Kong que protege la tecnología transdérmica AVERSA™ para la prevención del abuso. La patente, asignada con el número de publicación 40085268 B, se publicará el 20 de diciembre de 2024. La tecnología AVERSA™ ahora está protegida por patentes en 46 países, incluidos los mercados principales. Esta tecnología incorpora agentes aversivos en parches transdérmicos para prevenir el abuso de medicamentos como opioides y estimulantes. Nutriband está desarrollando AVERSA™ Fentanyl junto con Kindeva Drug Delivery, lo que podría convertirlo en el primer parche opioide con prevención del abuso en el mundo, con ventas anuales proyectadas en EE.UU. de 80 a 200 millones de dólares.
뉴스 테이프(이 저 면은 물론, 한국어가 없다]는 주식로는 편안한 페이지입니다. 누타이 바드 유한 회사는 AVERSA™의 글로벌 카피와 박스 노출에 대해게시 편안한 페이저입니다. 너무 말씀드린대로 Gloome 감수 전문 기본 기술이 CABCEDS로 뽑혀 품질을 중심으로 exlagned 명성이 강한 제품군들에 대한 사이트입니다.
Nutriband Inc. (NASDAQ:NTRB) a reçu un avis de publication pour son brevet à Hong Kong protégeant la technologie transdermique AVERSA™ contre l'abus. Le brevet, attribué avec le numéro de publication 40085268 B, sera publié le 20 décembre 2024. La technologie AVERSA™ est désormais protégée par des brevets dans 46 pays, y compris les principaux marchés. Cette technologie intègre des agents aversifs dans des patchs transdermiques pour prévenir l'abus de médicaments tels que les opiacés et les stimulants. Nutriband développe AVERSA™ Fentanyl avec Kindeva Drug Delivery, devenant potentiellement le premier patch opioïde dissuasif au monde, avec des ventes annuelles projetées aux États-Unis de 80 à 200 millions de dollars.
Nutriband Inc. (NASDAQ:NTRB) hat eine Veröffentlichungshinweis für sein Patent in Hongkong erhalten, das die AVERSA™-Technologie zum Schutz vor Missbrauch schützt. Das Patent mit der Veröffentlichungsnummer 40085268 B wird am 20. Dezember 2024 veröffentlicht. Die AVERSA™-Technologie ist nun durch Patente in 46 Ländern geschützt, einschließlich wichtiger Märkte. Diese Technologie integriert aversive Wirkstoffe in transdermale Pflaster, um den Missbrauch von Drogen wie Opioiden und Stimulanzien zu verhindern. Nutriband entwickelt zusammen mit Kindeva Drug Delivery das AVERSA™ Fentanyl, das potenziell das erste opioid-abweisende Pflaster der Welt werden könnte, mit geschätzten jährlichen Verkaufszahlen in den USA von 80 bis 200 Millionen Dollar.
- Patent protection expanded to Hong Kong, strengthening global IP portfolio across 46 countries
- Partnership with established manufacturer Kindeva Drug Delivery for AVERSA Fentanyl development
- Potential annual US sales of $80-200 million for AVERSA Fentanyl
- First-mover advantage in abuse-deterrent opioid patch market
- Product still in development phase with no immediate revenue generation
- Sales projections are estimates with no guarantee of market success
Insights
The Hong Kong patent grant significantly strengthens Nutriband's intellectual property portfolio for AVERSA™, now protected in 46 countries. This extensive IP coverage is important for potential peak annual US sales of
The Hong Kong market access adds strategic value beyond its immediate commercial potential. As a gateway to Asia's pharmaceutical market, this patent strengthens NTRB's position for potential licensing deals or partnerships in the region. The abuse-deterrent transdermal technology addresses a critical market need, especially given the global opioid crisis. With no current abuse-deterrent opioid patches available, AVERSA Fentanyl could capture significant market share. The comprehensive patent protection across major markets significantly enhances licensing potential and future revenue streams through partnerships or royalties.
AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch
ORLANDO, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong Intellectual Property Department for patent application entitled, “Abuse and Misuse Deterrent Transdermal Systems,” which protects its AVERSA™ abuse deterrent transdermal technology.
The Hong Kong Patents Registrar has assigned Publication Number 40085268 B to the patent with a publication date of December 20, 2024. Hong Kong is a Special Administrative Region (SAR) of the People’s Republic of China which affords it a high degree of autonomy with its own patent system and patent laws which are separate and distinct from those of mainland China.
The Aversa™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Nutriband’s AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. Preliminary studies have shown that the coating is very difficult to scrape off and the technology has a patented immediate and extended-release profile which presents an additional layer of deterrence to prevent the aversive layer from easily being washed off in an attempt to separate the drug from the aversive agents.
Nutriband is currently working with its partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA™ Fentanyl, which incorporates Nutriband’s AVERSA™ abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of
____________________________________________________
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q's filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Investor Relations
RedChip Companies, Inc.
Dave Gentry
Email: NTRB@Redchip.com
Phone: 1-800-RED-CHIP (733-2447)
or 407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
What is the potential market value for Nutriband's (NTRB) AVERSA Fentanyl patch?
How many countries have granted patents for Nutriband's (NTRB) AVERSA technology?
When will Nutriband's (NTRB) Hong Kong patent be published?
